Navigation Links
Relief From Asthma With New Combo Therapy

An inhaled corticosteroid (budesonide) coupled with a long-acting beta2-agonist (formoterol) can actually provide significant improvement of // asthma symptoms with less reliance on high doses of inhaled steroid, say researchers according to a new study.

For the study the effects of various combinations of medicine on asthma symptoms in 2,760 asthma patients at 246 centers in 22 countries were analyzed. The patients were divided into three treatment groups: a bud/form combination twice a day and as needed for relief, bud/form twice a day plus terbutaline (a short-acting beta2-agonist) as needed, and budesonide twice a day plus terbutaline as needed.

Results showed a 45-percent reduction in the exacerbation rate of asthma symptoms, a reduction in overall severe exacerbation levels, improved symptom control and lung function, and less sleep interruption in those who took the bud/form combo compared with the other two drug combinations. It was also observed that the bud/form combination helped maintain a reduction in asthma attacks severe enough to require medical attention, using a corticosteroid dose that was one-fourth the amount in the budesonide/terbutaline combo. Another positive finding from the study was that there was no evidence of a tolerance developing to the bud/form treatments, with patients maintaining their results for one year.
'"/>




Page: 1

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Relief from common back pain
3. Relief to pregnant women using fertility drugs
4. Relief of pain for suffering patients
5. Relief from cancer pain with anticonvulsants
6. Relief from Migraine
7. Pain Relief For Osteoarthritis Patients
8. Relief From Migraines
9. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
10. Drug Found To Bring Relief For Individuals With Early Parkinson’
11. Relief For Women Suffering From Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: